Inventors
Andy Tsun, Eric Krauland, Jonathan P. Belk, Xiaoniu Miao, Min Zhang, Nadthakarn Boland, Xiaolin Liu, Dechao YU.
Assignees
- INNOVENT BIOLOGICS (SUZHOU) CO., LTD. (Suzhou, Jiangsu, CN)
Abstract
The present invention provides an antibody that specifically binds to proprotein convertase subtilisin/kexin type 9 (PCSK9), an antigen-binding fragment of the antibody, and a composition comprising the antibody or the fragment. Also provided are a nucleic acid that encodes the antibody or the fragment, a host cell containing the nucleic acid, and applications of the antibody and fragment in treatment and diagnosis.
CovalX Technology Used (Click each option to learn more)
Epitope Mapping
XL Kits
Complex Tracker
HM4
Outcomes
This patent is for the invention of an antibody that binds to proprotein convertase subtilisin/kexin type 9 (PCSK9). It is known that PCSK9 activity is the main cause of pathological conditions such as cholesterol-related diseases, which can be diagnosed and treated using the antibodies and methods described in this patent.
CovalX’s HM4 interaction module was used with MALDI ToF MS for both before and during characterization to detect the anti-PCSK antibody and human PCSK9 (PCSK9-WT) separately and in a complex respectively. CovalX’s K200 MALDI MS analysis kit was also utilized where the antibody/antigen mixture was mixed with K200 Stabilizer reagent for MALDI analysis using HM4 module. At the end, MALDI ToF MS data were analyzed using CovalX Complex Tracker Analysis Software version 2.0.
Antibody/Antigen complex characterization conclusion was that anti-PCSK9 antibody can bind with both antigen PCSK9-WT Reduced and PCSK9-WT.